KNOW-Ped CKD (KoreaN cohort study for outcomes in patients with pediatric CKD): Design and methods

BMC Nephrology

Study Protocol

Curie Ahn¹  Kook Hwan Oh¹  Young Seo Park²  Joo Hoon Lee²  Kyung Hee Han³  Min Hyun Cho⁴  Seong Heon Kim⁵  Hee Yeon Cho⁶  Il-Soo Ha⁷  Hee Gyung Kang⁷  Hae Il Cheong⁷  Hyun Jin Choi⁷  Jae Il Shin⁸  Joongyub Lee⁹ 

[1]Department of Internal Medicine, Seoul National University Children’s Hospital, Seoul, South Korea

[2]Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

[3]Department of Pediatrics, Jeju University Hospital, Jeju, South Korea

[4]Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, South Korea

[5]Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, South Korea

[6]Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

[7]Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, South Korea

[8]Department of Pediatrics, Yonsei University College of Medicine, Severance Children’s Hospital, Seoul, South Korea

[9]Department of Preventive Medicine, Seoul National University Hospital, Seoul, South Korea

关键词: Chronic kidney disease;    Cohort study;    Design;    Prognostic factor;    Asian children;   

DOI  :  10.1186/s12882-016-0248-0

 received in 2015-10-29, accepted in 2016-03-18,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundThe global prevalence of chronic kidney disease (CKD) is increasing. In children, CKD exhibits unique etiologies and can have serious impacts on children’s growth and development. Therefore, an aggressive approach to preventing the progression of CKD and its complications is imperative. To improve the understanding and management of Asian pediatric patients with CKD, we designed and launched KNOW-Ped CKD (KoreaN cohort study for Outcome in patients With Pediatric Chronic Kidney Disease), a nationwide, prospective, and observational cohort study of pediatric CKD with funding from the Korean government.Methods/designFrom seven major centers, 450 patients <20 years of age with CKD stages I to V are recruited for the comprehensive assessment of clinical findings, structured follow-up, and bio-specimen collection. The primary endpoints include CKD progression, defined as a decline of estimated glomerular filtration rate by 50 %, and a requirement for renal replacement therapy or death. The secondary outcomes include the development of left ventricular hypertrophy or hypertension, impairment of growth, neuropsychological status, behavioral status, kidney growth, and quality of life.DiscussionWith this study, we expect to obtain more information on pediatric CKD, which can be translated to better management for the patients.Trial registrationNCT02165878 (ClinicalTrials.gov), submitted on June 11, 2014.

【 授权许可】

CC BY   
© Kang et al. 2016